Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia

BJU International

Volumn 113, Issue 1, 2014, Pages 77-83

  Ranasinghe, Weranja K B ^a   Kim, Simon P ^b   Lawrentschuk, Nathan ^c,d   Sengupta, Shomik ^c   Hounsome, Luke ^e   Barber, Jim ^f   Jones, Richard ^g   Davis, Paul ^h   Bolton, Damien ^c   Persad, Raj ⁱ  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e South West Public Health Observatory ^*  (United Kingdom)

^f VELINDRE CANCER CENTRE   (United Kingdom)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h FRANKSTON HOSPITAL   (Australia)

ⁱ UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Australia; incidence; prostate cancer; PSA screening; young men

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ARTICLE; AUSTRALIA; CANCER GRADING; CANCER INCIDENCE; CANCER SCREENING; COMPARATIVE STUDY; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SCREENING TEST; TRANSRECTAL ULTRASONOGRAPHY; TREND STUDY; VERY ELDERLY;

AUSTRALIA; INCIDENCE; PROSTATE CANCER; PSA SCREENING; YOUNG MEN;

ADULT; AGE DISTRIBUTION; AUSTRALIA; HUMANS; IMAGE-GUIDED BIOPSY; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84890552695     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12354     Document Type: Article

References (36)

1. Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10 [Internet] [database on the Internet]. Lyon, France: International Agency for Research on Cancer, 2010. Available at: http://globocan.iarc.fr. Accessed 9 April 2013
2. Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. Australian Institute of Health and Welfare 2012
3. Welch HG, Albertsen PC,. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325-1329
4. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990
5. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125-132
6. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155: 762-771
7. Australian Bureau of Statistics. Australian Bureau of Statistics. 2012 Available at: http://www.abs.gov.au/. Accessed November 2012
8. Australian Institute of Health and Welfare Cancer Datacubes. Australian Institute of Health and Welfare. 2012. Available at: http://www.aihw.gov.au/ cancer-data/. Accessed November 2012
9. Australia TCC. National Cancer Prevention Policy 2007-09. Camperdown, NSW: Australia TCC, 2007
10. Urology Society of Australia and New Zealand. Urological Society of Australia and New Zealand PSA Testing Policy 2009. Edgecliff, NSW: Urological Society of Australia and New Zealand, 2009. Available at: http://www.usanz.org. au/uploads/29168/ufiles/USANZ-2009-PSA-Testing-Policy-Final1.pdf. Accessed 9 April 2013
11. Segi M,. Cancer Mortality for Selected Sites in 24 Countries (1950-57). Sendai, Japan: Tohoku University of Medicine, 1960
12. Victorian Cancer Registry. Victorian Cancer registry. 2012. Available at: http://www.cancervic.org.au/about-our-research/registry-statistics/vcr. Accessed October 2012
13. Kim HJ, Fay MP, Feuer EJ, Midthune DN,. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-351
14. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328
15. Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schroder FH, Vickers AJ,. Risk-based prostate cancer screening. Eur Urol 2012; 61: 652-661
16. The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice (6th edition). ISBN 0-869-062-700. September 2005
17. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012; 367: 595-605
18. Lilja H, Cronin AM, Dahlin A, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117: 1210-1219
19. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. United States Cancer Statistics: 1999-2008 Incidence and Mortality Web-Based Report. Atlanta, 2013
20. Ilic D, Neuberger MM, Djulbegovic M, Dahm P,. Screening for prostate cancer. Cochrane Database Syst Rev 2013; (1): CD004720
21. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M,. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 2007; 100: 540-543
22. Davison BJ, Goldenberg SL,. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. BJU Int 2011; 108: 1787-1793
23. Kasperzyk JL, Shappley WV, 3rd, Kenfield SA, et al. Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study. J Urol 2011; 186: 1862-1867
24. Crawford ED, Black L, Eaddy M, Kruep EJ,. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 162-167
25. Lin K, Lipsitz R, Miller T, Janakiraman S,. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 192-199
26. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM,. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186: 1830-1834
27. Miller J, Perumalla C, Heap G,. Complications of transrectal versus transperineal prostate biopsy. ANZ J Surg 2005; 75: 48-50
28. Yin M, Bastacky S, Chandran U, Becich MJ, Dhir R,. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol 2008; 179: 892-895; discussion 5
29. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
30. Carroll PAP, Greene K, et al. American Urological Assocation prostate- specific antigen best practice statement: 2009 update. 2009. Available at: http://www.auanet.org/content/media/psa09.pdf. Accessed 9 April 2013
31. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60: 70-98
32. Kawachi MH, Bahnson RR, Barry M, et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw 2010; 8: 240-262
33. Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2012; 30: 3020-3025
34. Zhu X, van Leeuwen PJ, Bul M, Bangma CH, Roobol MJ, Schroder FH,. Identifying and characterizing 'escapes'-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam). Int J Cancer 2011; 129: 2847-2854
35. Droz JP, Balducci L, Bolla M, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010; 106: 462-469
36. Litchfield MJ, Cumming RG, Smith DP, et al. Prostate-specific antigen levels in men aged 70 years and over: findings from the CHAMP study. Med J Aust 2012; 196: 395-398